The Priceline of Cannabis up 213% in 2017 - More to Come?

Analysis originally distributed on September 27, 2017 By: Michael Vodicka of Cannabis Stock Trades

The Priceline Group Inc. (NASDAQ:PCLN) has been one of the best performing stocks in the S&P 500 for the last ten years.

Priceline's gain of 1,970% destroyed the S&P 500's 64% return in the same period. Take a look below.

Priceline

Investing $1,000 ten years ago would be worth $19,700 today.

Investing $10,000 ten years ago would be worth $197,000.

The reason for Priceline's success is simple. It uses technology to help consumers find great deals.

Today - I see this same cycle repeating itself in the cannabis sector. Continue reading "The Priceline of Cannabis up 213% in 2017 - More to Come?"

3 Cannabis Stocks Profiting from Germany's New Medical Program

Analysis originally distributed on September 20, 2017 By: Michael Vodicka of Cannabis Stock Trades

Germany is quickly beginning to look like the next mega market for medical and eventually recreational cannabis. This is creating another big opportunity for savvy investors who are following the story and staying ahead of the curve.

Today, I am going to show you how you can profit.

But first - a little background.

Germany is the beating heart of Europe.

It is the largest country in the European Union with a population of 81 million.

It also has the largest economy in the European Union by a long shot. Its gross domestic product clocked in at $3.5 billion in 2016. Its per capita GDP of $42,000 makes it one of the wealthiest countries in Europe.

Companies that can gain access to the German consumer market have an opportunity to access tens of millions of wealthy consumers.

This is particularly true in Germany's young medical cannabis market. Continue reading "3 Cannabis Stocks Profiting from Germany's New Medical Program"

Hemp For Pets Company Up 122% In 2017

Analysis originally distributed on September 14, 2017 By: Michael Vodicka of Cannabis Stock Trades

Pets are big business in the US and around across the globe.

In 2016 U.S. consumers spent over $67 billion on pet-related products, up 11% from the year before.

While food accounts for the highest percent of spending, pet medications were close behind at $8 billion. Spending on pet medications is expected to grow another 10% in 2017 to $9 billion.

These huge sales numbers have gotten the attention of the cannabis industry. Capturing even a small percent of the pet medication market could mean hundreds of millions in profit.

That's why I am excited to share an early industry leader that most investors have never heard of.

- Sales are up more than 1,000% in the last 12 months.
- Shares have risen 122% since January.

With the cannabis for pets industry still in its early stages - I see plenty of room for growth for this undercover cannabis company. True Leaf Medicine International Ltd. (TRLFF) is a Canadian cannabis company founded in 2013 and headquartered in British Columbia.

Trueleaf

Shares are listed on the Canadian Securities Exchange under the ticker symbol MJ. I see average daily trading volume around 100,000 shares here, so this stock has plenty of liquidity for most investors. Continue reading "Hemp For Pets Company Up 122% In 2017"

Australian Cannabis Biotech Up 271%

Analysis originally distributed on August 30, 2017 By: Michael Vodicka of Cannabis Stock Trades

Opioid abuse has quickly grown into a major global epidemic.

While opioids can be great for pain relief, the down side is that they are highly addictive. Recent data shows that opioid abuse and addiction is killing tens of thousands of people every year in just the United States.

Overdose deaths caused by prescription opioids have quadrupled since 1999. From 1999 to 2015, more than 183,000 people have died in the U.S. from overdoses related to prescription opioids.

This is an alarming trend that has both patients and health care professionals asking - are we capable of providing a better alternative?

According to a young biotech located Australia the answer is yes - and the solution comes in the form of cannabis.

If this young cannabis biotech is correct, not only will patients benefit, early shareholders will be rewarded with huge gains.

Let's take a look. Continue reading "Australian Cannabis Biotech Up 271%"

Australian Cannabis Biotech Developing Cancer and Epilepsy Drugs

Analysis originally distributed on August 23, 2016 By: Michael Vodicka of Cannabis Stock Trades

MGC Pharmaceuticals (TSX:MXC, OTC:MGCLF) is a young cannabis biotech headquartered in Western Australia that specializes in pharmaceutical product research and development.

MGC

Australian cannabis stocks have been red hot for the last few months.

  • I added Australian-based Cann Group (ASX:CAN) to the members portfolio on July 31 and we're already up 70% in less than three weeks.
  • I added fellow Australian cannabis stock AusCann (OTC:ACNNF) to the member portfolio on June 6 and we're up 55%.

If you want to learn more about our member portfolio click here.

Although the company is incorporated and headquartered in Australia it also has operations in both Israel and Europe.

For example, MGC received two licenses from the Slovenian government to grow, process and trade Cannabis Sativa L (Hemp) and its products, including Cannabidoil (CBD) resin, in Europe.

The company's founders were leaders in Israel's growing medical cannabis industry. Continue reading "Australian Cannabis Biotech Developing Cancer and Epilepsy Drugs"